542650 Overzicht aandelen Metropolis Healthcare Limited levert diagnostische diensten in India en daarbuiten. Meer informatie
Beloningen Risicoanalyse Geen risico's gedetecteerd voor 542650 uit onze risicocontroles.
Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Metropolis Healthcare Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Metropolis Healthcare Historische aandelenkoersen Huidige aandelenkoers ₹1,992.80 52 Week Hoogtepunt ₹2,306.85 52 Week Laag ₹1,450.05 Bèta 0.34 1 maand verandering -6.70% 3 maanden verandering -9.23% 1 Jaar Verandering 19.07% 3 jaar verandering -39.07% 5 jaar verandering 22.80% Verandering sinds IPO 107.68%
Recent nieuws en updates Metropolis Healthcare Limited (NSEI:METROPOLIS) agreed to acquire Core Diagnostics Private Limited from Core Diagnostics (Mauritius) Private Limited for INR 2.46 billion. Dec 10
Metropolis Healthcare Limited Announces Management Changes Nov 28
Second quarter 2025 earnings: EPS misses analyst expectations Nov 09
Metropolis Healthcare Limited Appoints Aditya Shinde as Interim Chief Financial Officer, Effective November 11, 2024 Nov 08
Metropolis Healthcare Limited to Report Q2, 2025 Results on Nov 08, 2024 Oct 31 Metropolis Healthcare Limited Announces Resignation of Rakesh Agarwal as Chief Financial Officer, Effective November 10, 2024 Oct 12
Meer updates bekijken Metropolis Healthcare Limited (NSEI:METROPOLIS) agreed to acquire Core Diagnostics Private Limited from Core Diagnostics (Mauritius) Private Limited for INR 2.46 billion. Dec 10
Metropolis Healthcare Limited Announces Management Changes Nov 28
Second quarter 2025 earnings: EPS misses analyst expectations Nov 09
Metropolis Healthcare Limited Appoints Aditya Shinde as Interim Chief Financial Officer, Effective November 11, 2024 Nov 08
Metropolis Healthcare Limited to Report Q2, 2025 Results on Nov 08, 2024 Oct 31 Metropolis Healthcare Limited Announces Resignation of Rakesh Agarwal as Chief Financial Officer, Effective November 10, 2024 Oct 12
Metropolis Healthcare Limited Appoints Pinakin Shah as Chief Information Officer Sep 07 Metropolis Healthcare Limited Announces Changes in Board
Founder & Chairman Emeritus recently sold ₹136m worth of stock Aug 22
Metropolis Healthcare Limited to Report Q1, 2025 Results on Aug 10, 2024 Aug 05
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 02 Metropolis Healthcare Limited, Annual General Meeting, Aug 21, 2024
Metropolis Healthcare Limited, Annual General Meeting, Aug 21, 2024 Jul 29
Founder & Chairman Emeritus recently sold ₹51m worth of stock Jun 13
Price target increased by 7.4% to ₹1,861 Jun 08
Metropolis Healthcare Limited Appoints Sushil Shah as Chairman Emeritus, Effective May 22, 2024 May 23
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 22
Metropolis Healthcare Limited to Report Q4, 2024 Results on May 21, 2024 May 16
Founder & Executive Chairman recently sold ₹62m worth of stock Apr 03
Third quarter 2024 earnings: EPS misses analyst expectations Feb 05
Metropolis Healthcare Limited Announces Management Changes Feb 02
Metropolis Healthcare Limited to Report Q3, 2024 Results on Feb 02, 2024 Jan 27
Upcoming dividend of ₹4.00 per share at 0.5% yield Nov 10
Price target increased by 7.4% to ₹1,528 Nov 07
Second quarter 2024 earnings: EPS misses analyst expectations Nov 07
Metropolis Healthcare Limited to Report Q2, 2024 Results on Nov 04, 2023 Oct 29
Metropolis Healthcare Limited Announces the Cessation of Milind Sarwate as an Independent Director, Chairman/Member of Audit Committee, Risk Management Committee and Corporate Social Responsibility Committee, Effective September 06, 2023 Sep 07
Metropolis Healthcare Limited to Report Q1, 2024 Results on Aug 02, 2023 Jul 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Jul 26
Metropolis Healthcare Limited, Annual General Meeting, Aug 17, 2023 Jul 24
Metropolis Healthcare Limited Appoints Neha Shah as Interim Company Secretary Jun 22
Insufficient new directors Jun 01
Price target decreased by 7.5% to ₹1,397 May 19
Full year 2023 earnings: EPS and revenues miss analyst expectations May 17
Metropolis Healthcare Limited to Report Q4, 2023 Results on May 16, 2023 May 11
Upcoming dividend of ₹8.00 per share at 0.6% yield Feb 16
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Feb 12
Metropolis Healthcare Limited Declares Interim Dividend for the Financial Year 2022-23 Feb 11
Metropolis Healthcare Limited to Report Q3, 2023 Results on Feb 10, 2023 Feb 04
Second quarter 2023 earnings: EPS misses analyst expectations Nov 10
Metropolis Healthcare Limited to Report Q2, 2023 Results on Nov 08, 2022 Nov 02
Metropolis Healthcare Limited Announces Resignation of Vijender Singh as Chief Execution Officer Aug 19
Metropolis Healthcare Limited Proposes to Confirm the Payment of Interim Dividend for the Financial Year Ended March 31, 2022 Aug 18
Price target decreased to ₹1,746 Aug 14
Metropolis Healthcare Limited to Report Q1, 2023 Results on Aug 10, 2022 Aug 04
Metropolis Healthcare Limited Announces Resignation of Chief Executive Officer, Effective November 30, 2022 Jul 30
Full year 2022 earnings: EPS and revenues miss analyst expectations Jul 28
Metropolis Healthcare Limited, Annual General Meeting, Aug 17, 2022 Jul 22
Metropolis Healthcare Limited to Report Q4, 2022 Final Results on Jul 18, 2022 Jul 13
GSK Velu Reportedly in Talks with Investors, PEs & Banking Firms to Buy Back Metropolis Healthcare Jun 15 Metropolis Confirms Promoters Have No Intention to Exit the Business
Adani, Apollo Reportedly Explore Bids for Majority Stake in Metropolis Jun 07
Price target decreased to ₹2,461 May 26
Full year 2022 earnings: EPS and revenues miss analyst expectations May 26
Amazon, Flipkart Reportedly in Talks to Buy Stake in Metropolis Healthcare May 21
Metropolis Healthcare Limited to Report Q4, 2022 Results on May 24, 2022 May 17
Investor sentiment improved over the past week Apr 05
Founder & Executive Chairman recently bought ₹100m worth of stock Feb 23
Investor sentiment deteriorated over the past week Feb 18
Upcoming dividend of ₹8.00 per share Feb 14
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Feb 13
Metropolis Healthcare Limited Declares Payment of an Interim Dividend Feb 12
Metropolis Healthcare Limited to Report Q3, 2022 Results on Feb 11, 2022 Feb 04
Investor sentiment deteriorated over the past week Jan 24
Insider recently sold ₹820k worth of stock Jan 01
Price target increased to ₹2,998 Dec 01
Founder & Executive Chairman recently sold ₹1.3b worth of stock Nov 18
Second quarter 2022 earnings released: EPS ₹11.39 (vs ₹11.88 in 2Q 2021) Nov 11
High number of new directors Oct 31
Key Executive recently sold ₹4.8m worth of stock Sep 14
Insider recently sold ₹1.7m worth of stock Sep 04
Price target increased to ₹2,789 Aug 09
Full year 2021 earnings released: EPS ₹35.97 (vs ₹25.36 in FY 2020) Jul 20
Suburban Diagnostics Reportedly in Sale Talks with Dr. Lal PathLabs, Metropolis, Pharmeasy, Others Jun 18
Company Secretary & Compliance Officer Poonam Tanwani has left the company Jun 04
Insider recently sold ₹7.8m worth of stock Jun 03
Price target increased to ₹2,466 May 31
Full year 2021 earnings released: EPS ₹35.97 (vs ₹25.36 in FY 2020) May 30
Chief Executive Officer recently sold ₹5.2m worth of stock Mar 31
Insider recently sold ₹999k worth of stock Mar 23
Chief Executive Officer recently sold ₹109m worth of stock Feb 24
Third quarter 2021 earnings released: EPS ₹11.50 (vs ₹8.38 in 3Q 2020) Feb 12
Revenue and earnings miss expectations Feb 12
Metropolis Healthcare Limited Revises Constitution of the Nomination and Remuneration Committee, with Effect from February 10, 2021 Feb 11
Metropolis Healthcare Limited to Report Q3, 2021 Results on Feb 10, 2021 Feb 05
Price target raised to ₹2,193 Jan 19
Metropolis Healthcare Limited (NSEI:METROPOLIS) agreed to acquire Dr. Ganesan's Hitech Diagnostic Centre Private Limited from Ganesan Subramanian, Manimegalai Ganesan and Malini Parasuraman for INR 6.2 billion. Jan 19
Insider recently sold ₹2.7m worth of stock Jan 08
Insider recently sold ₹2.0m worth of stock Dec 12
Insider recently sold ₹2.0m worth of stock Nov 21
New 90-day high: ₹2,040 Nov 18
Price target raised to ₹2,034 Nov 14
Second quarter 2021 earnings released: EPS ₹11.88 Nov 14
Revenue and earnings beat expectations Nov 14
Metropolis Healthcare Limited (NSEI:METROPOLIS) completed the acquisition of remaining 49% stake in Raj Metropolis Healthcare Private Limited. Nov 06 Rendement voor aandeelhouders 542650 IN Healthcare IN Markt 7D -3.2% 2.7% 1.6% 1Y 19.1% 37.7% 17.5%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 542650 presteerde slechter dan de Indian Healthcare -sector, die het afgelopen jaar een rendement van 37.7 % opleverde.
Rendement versus markt: 542650 overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 17.5 %.
Prijsvolatiliteit Is 542650's price volatile compared to industry and market? 542650 volatility 542650 Average Weekly Movement 3.8% Healthcare Industry Average Movement 5.2% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Stabiele aandelenkoers: 542650 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van 542650 is het afgelopen jaar stabiel geweest.
Over het bedrijf Metropolis Healthcare Limited levert diagnostische diensten in India en internationaal. Het bedrijf biedt klinische laboratoriumtests en profieldiensten aan. Het biedt ook diagnostische diensten voor oncologie, neurologie, gynaecologie en nefrologie, evenals verschillende gezondheidscontrolepakketten voor mannen, vrouwen, senioren, jongeren en bedrijven.
Meer tonen Metropolis Healthcare Limited Samenvatting Hoe verhouden de winst en inkomsten van Metropolis Healthcare zich tot de beurswaarde? 542650 fundamentele statistieken Marktkapitalisatie ₹102.42b Inkomsten(TTM ) ₹1.48b Inkomsten(TTM ) ₹12.85b
69.2x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 542650 resultatenrekening (TTM ) Inkomsten ₹12.85b Kosten van inkomsten ₹2.84b Brutowinst ₹10.01b Overige uitgaven ₹8.53b Inkomsten ₹1.48b
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) 28.87 Brutomarge 77.88% Nettowinstmarge 11.52% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde 542650 op de lange termijn?
Bekijk historische prestaties en vergelijking Dividenden
0.2% Huidig dividendrendement
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/05 08:05 Aandelenkoers aan het einde van de dag 2025/01/03 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2024/03/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Metropolis Healthcare Limited wordt gevolgd door 33 analisten. 17 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Prashant Nair Ambit Capital null null Antique Stockbroking Ltd. Harith Ahamed Avendus Spark
Toon 30 meer analisten 
